These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21408188)

  • 1. The association of mid-regional pro-adrenomedullin and mid-regional pro-atrial natriuretic peptide with mortality in an incident dialysis cohort.
    Gouya G; Sturm G; Lamina C; Zitt E; Freistätter O; Struck J; Wolzt M; Knoll F; Lins F; Lhotta K; Neyer U; Kronenberg F
    PLoS One; 2011 Mar; 6(3):e17803. PubMed ID: 21408188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
    Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
    Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) in severe aortic valve stenosis: association with outcome after transcatheter aortic valve implantation (TAVI).
    Baldenhofer G; Laule M; Mockel M; Sanad W; Knebel F; Dreger H; Leonhardt F; Sander M; Grubitzsch H; Baumann G; Stangl K; Stangl V
    Clin Chem Lab Med; 2017 Feb; 55(2):275-283. PubMed ID: 27522619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction.
    Jensen J; Schou M; Kistorp C; Faber J; Hansen TW; Jensen MT; Andersen HU; Rossing P; Vilsbøll T; Jørgensen PG
    Cardiovasc Diabetol; 2020 Oct; 19(1):180. PubMed ID: 33066783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
    Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
    Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
    Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
    Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain.
    Tzikas S; Keller T; Ojeda FM; Zeller T; Wild PS; Lubos E; Kunde J; Baldus S; Bickel C; Lackner KJ; Münzel TF; Blankenberg S
    Heart; 2013 Mar; 99(6):388-95. PubMed ID: 23213173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study.
    Schnabel RB; Wild PS; Schulz A; Zeller T; Sinning CR; Wilde S; Kunde J; Lubos E; Lackner KJ; Warnholtz A; Gori T; Blankenberg S; Munzel T;
    Hypertension; 2012 Aug; 60(2):288-95. PubMed ID: 22689741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of mid-regional pro-atrial natriuretic peptide, procalcitonin, and mid-regional pro-adrenomedullin for the diagnosis and risk stratification of dyspneic ED patients.
    Cinar O; Cevik E; Acar A; Kaya C; Ardic S; Comert B; Yokusoglu M; Bilgi C; Meisner M; Madsen T
    Am J Emerg Med; 2012 Nov; 30(9):1915-20. PubMed ID: 22742951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of mid-regional pro-adrenomedullin levels to cardiovascular and metabolic abnormalities, and mortality in an elderly population from the community.
    Eggers KM; Venge P; Lindahl B; Lind L
    Int J Cardiol; 2013 Oct; 168(4):3537-42. PubMed ID: 23722054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study.
    Frøssing S; Nylander M; Aziz M; Skouby SO; Kistorp C; Faber J
    Gynecol Endocrinol; 2017 Jan; 33(1):30-33. PubMed ID: 27424881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 16. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial.
    Maisel A; Mueller C; Nowak R; Peacock WF; Landsberg JW; Ponikowski P; Mockel M; Hogan C; Wu AH; Richards M; Clopton P; Filippatos GS; Di Somma S; Anand I; Ng L; Daniels LB; Neath SX; Christenson R; Potocki M; McCord J; Terracciano G; Kremastinos D; Hartmann O; von Haehling S; Bergmann A; Morgenthaler NG; Anker SD
    J Am Coll Cardiol; 2010 May; 55(19):2062-76. PubMed ID: 20447528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study.
    Bosselmann H; Egstrup M; Rossing K; Gustafsson I; Gustafsson F; Tonder N; Kistorp CN; Goetze JP; Schou M
    Int J Cardiol; 2013 Dec; 170(2):202-7. PubMed ID: 24182673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study.
    Holm H; Nägga K; Nilsson ED; Ricci F; Melander O; Hansson O; Bachus E; Magnusson M; Fedorowski A
    J Intern Med; 2017 Jul; 282(1):94-101. PubMed ID: 28407377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular biomarkers predict fragility fractures in older adults.
    Johansson M; Ricci F; Di Martino G; Rogmark C; Sutton R; Hamrefors V; Melander O; Fedorowski A
    Heart; 2019 Mar; 105(6):449-454. PubMed ID: 30322844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of circulating MR-proADM with all-cause and cardiovascular mortality in the general population: Results from the KORA F4 cohort study.
    Gar C; Thorand B; Herder C; Sujana C; Heier M; Meisinger C; Peters A; Koenig W; Rathmann W; Roden M; Stumvoll M; Maalmi H; Meitinger T; Then H; Seissler J; Then C
    PLoS One; 2022; 17(1):e0262330. PubMed ID: 34990470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.